Distalmotion told MedTech Dive last week that DEXTER has crossed 3,000 procedures, that Q1 2026 was the company’s strongest quarter to date, and that the first U.S. ambulatory surgery center installation went live in Wichita in March. The platform is purpose-built for the ASC: 125-square-foot footprint, four-minute setup, single-use instruments that eliminate the sterilization workflow, open architecture that accepts third-party visualization. While Intuitive’s installed base sits in 6,000-plus hospitals, the next decade of U.S. surgical procedure volume is migrating into the 6,400 Medicare-certified ASCs, and the surgical robotics platform that meets the ASC spec is the one positioned to compound through the shift. The founders who finish in surgical robotics are designing for the site where the volume is going, from initial product architecture, before the procedural migration shows up in their commercial pipeline.
If You Are Building a Company in This Environment
The default first-time surgical robotics founder designs the platform for the hospital operating room. The internal logic is that the hospital OR is where the installed base of competitive robots sits, the academic medical center is where surgeon adoption begins, and the procurement budget for surgical capital equipment is concentrated in the same purchasing committee that already approved the predicate platforms. Most founders make that call without thinking about it, because the plan looks responsible. The robot is engineered around the OR room dimensions, the OR power infrastructure, the OR sterilization workflow, and the OR teaching environment. The product fits the room where the surgeons are trained today.
That plan misreads where the procedure volume is actually moving. Medicare-certified ASCs grew at an average annual rate of 2.2% over five years, exceeding 6,400 facilities, while hospital openings have lagged closures over a 14-year window through 2023. The procedural categories that are migrating fastest into the ASC channel are exactly the categories surgical robotics platforms target: hernia repair, gallbladder removal, hysterectomy, sacrocolpopexy, and the broader range of soft-tissue laparoscopic procedures that drive the addressable market the founders pitched in their fundraising decks. Distalmotion has been engineered for the ASC environment, has surpassed 3,000 procedures, and is now installing in U.S. ambulatory surgery centers while the legacy hospital-OR platforms continue to be evaluated against ASC procurement specs they were never designed to meet.
The retrofit version of ASC adaptation is far more expensive and far less effective than the from-architecture version. A hospital-OR robot redesigned for the ASC environment requires footprint reduction, sterilization workflow simplification, capital cost compression, setup-time engineering, and a commercial model that fits the smaller capital budget of the freestanding ASC. The redesign work is years long, carries regulatory rework on the cleared platform, and produces a hybrid product that fits neither environment cleanly. The founder who deferred the ASC architecture until after first hospital clearance discovers in the middle of the first commercial cycle that the procedural migration is moving faster than the redesign can be completed.
The Pattern That Costs Surgical Robotics Founders the Site They Will Need
The pattern that breaks first-time surgical robotics founders on the site shift is treating the ASC environment as a future market that can be addressed with a simplified version of the hospital-OR platform. The pattern produces a predictable timeline. The company ships the cleared platform into a small number of academic medical centers, builds early case volume in the hospital OR, raises the next round on the strength of the early hospital adoption, and then meets the ASC market in head-to-head selection processes against platforms purpose-built for the site. The ASC procurement committee asks how the platform fits the existing room dimensions, how the sterilization workflow integrates with the limited central processing capacity, and what the all-in capital and per-procedure economics look like at ASC scale. The hospital-OR platform has answers that are roadmap items rather than shipping capabilities, and the procurement decision goes to the platform that meets the spec today.
The cost shows up in two specific places. The first is procedural-volume capture as the migration accelerates. A surgical robotics platform that is not winning ASC placements during the migration is locked out of the procedure volume that drives the hospital purchasing logic for robotic platforms in the first place, and the hospital sees the ASC vendor capture procedural growth that the hospital can no longer count on retaining. The second is investor and strategic-acquirer diligence at the next round. Sophisticated investors are now asking specifically about the ASC commercial trajectory, the ASC product-market fit, and the multi-site footprint compatibility, and they are pricing the company on the post-shift addressable market rather than on the legacy hospital-OR base. A platform without a credible ASC strategy raises against a different multiple than one with shipping ASC placements.
The companies that finish in this environment do the opposite. They treat the ASC environment as the design center for the platform from initial architecture, fund the small-footprint, fast-setup, single-use-instrument engineering as a Day-1 capital line, and protect it during the busy quarters when the obvious operational pressure is on hospital adoption. The work is harder during the run-up to first clearance, and it produces the platform that wins the next phase of the procedural-volume capture.
What ASC-Ready Discipline Looks Like at Operating Scale
The companies that win on the site-of-care shift do specific work that is easy to defer and expensive to skip. They size the platform to fit the smaller ASC OR from initial industrial design, with the floor footprint, the power and air infrastructure, and the room-flow dimensions all tested against the actual ASC environment, not against the academic medical center where the prototype work happened. They engineer the sterilization workflow to fit the limited central processing capacity at the freestanding ASC, including the choice between single-use instruments and the simplified reprocessing protocol. They design the platform setup time and the surgeon learning curve around the operational tempo of the ASC, where room turnover is a primary economic lever and a multi-hour setup destroys the case-volume model.
At the operating level, this discipline shows up as a single product architecture that ships across both site types, not as a hospital platform with an ASC variant on a future roadmap. The commercial model includes capital structures that match the ASC budget, including financing programs, per-case economics, and partnership models with the ASC management companies and the surgeon-owned ASC networks that own the largest concentration of installations in the U.S. The clinical evidence base includes case series and outcomes data that prove the platform performs in the ASC environment, not just in the controlled academic medical center setting where the predicate trials were run. Founders who finish run the ASC track in parallel with the hospital track from initial commercial launch, with the same operational rigor and the same investment intensity.
The Distalmotion story is the cleanest current example of what the discipline produces. The platform was engineered for the lower-acuity site of care from initial industrial design, the FDA de novo clearance program built indication breadth across hernia, gallbladder, hysterectomy, and the pending uro-gynecology indications, and the commercial program landed the first U.S. ASC installation in early 2026 against the ongoing hospital adoption. J&J’s strategic investment is the signal that the strategic acquirers are pricing the ASC-ready platform on a different curve than the hospital-OR-only legacy platforms.
The Five Questions for the Surgical Robotics Platform Founder
The five-question framework in Founders Who Finish reframes what an ASC-ready surgical robotics platform actually requires the team to deliver, and where the operational risk concentrates.
Question 1
What are you actually finishing?
If the answer is a cleared hospital-OR robot, the company is finishing the predecessor product to the platform that the next decade of procedure volume will require. The cleared robot that fits both the hospital OR and the ASC, with the workflow and economics that allow the same platform to ship into both environments, is the actual completion state. Founders who finish are running the ASC architecture track in parallel with the hospital clearance track, not after.
Question 2
Who decides you are done?
The ASC procurement committee evaluating soft-tissue robotic platforms decides, alongside the hospital purchasing committee. ASC committees evaluate platforms against room dimensions, sterilization capacity, capital budgets, and case-turnover economics that the hospital-OR platforms were not engineered to meet. Founders who finish have engaged ASC procurement and ASC management companies for years before the evaluation, and have shown those committees the platform fitted to the actual room and workflow.
Question 3
What does your evidence actually prove?
Hospital-OR clinical evidence proves the platform works in a controlled academic medical center. ASC evidence proves the platform delivers the case throughput, the workflow integration, and the economic outcomes the ASC model requires. Founders who finish design the ASC-specific evidence base on the same cadence as the hospital evidence, including the case volume studies, the sterilization workflow validation, and the per-case economics across the freestanding and hospital-affiliated ASC environments.
Question 4
What does your path to reimbursement look like?
The reimbursement environment for ASC-based robotic procedures depends on the site-of-service differential, the CPT code and procedure-fee structure, and the ASC payment system rules that determine which cases the freestanding ASC can profitably perform. A platform with a single-site-of-service economics case will struggle in the multi-site environment that strategic acquirers and large hospital systems are operating in. Founders who finish run a reimbursement strategy that proves the per-case economics across the hospital OR, the hospital outpatient department, and the freestanding ASC.
Question 5
What does the finish line look like to a strategic acquirer?
Strategic acquirers of surgical robotics platforms now pay premiums for platforms with shipping ASC placements, ASC-ready architecture, multi-site clinical evidence, and a commercial model that captures procedure volume across both sides of the site shift. They pay much smaller premiums for hospital-OR-only platforms with ASC strategies still on the roadmap. Founders who finish position the company to land in the first category, and the ASC-ready discipline that produces that positioning has to be embedded from initial product architecture.
Founders Who Finish
The guide for founders building in regulated markets
The five-question framework for building medical device, surgical robotics, and advanced interventional companies that finish what they start, in the regulatory and operational environment as it actually exists.
Get the Book